Diagnostic value of some subjective and objective symptoms of gastric ulcer.

Some subjective and objective symptoms, that are believed to be specific of peptic ulcer, were analyzed in 425 patients with endoscopically confirmed gastric ulcer. It was noted that the pain syndrome may have variants while pain after meals remains a typical sign of gastric ulcer. But asthenic habitus, tendency to sinus bradycardia and arterial hypotension, the absence of a coated tongue, and the tendency to erythrocytosis and decelerated ESR were not typical for the observed patients. The results suggest that some traditional concepts of typical clinical picture of peptic ulcer should be revised.     

Esaprazole in the treatment of gastric ulcer: preliminary clinical trial

The activity and tolerability of esaprazole administered once a day at doses of 900 and 1350 mg/day in the treatment of gastric ulcer were evaluated in a preliminary study carried out in 47 patients. The results failed to show any difference between the two doses in terms of percentage of ulcer healing after 4 weeks (43% and 45% respectively) or 8 weeks (86% and 82%), or in the course of symptoms and signs, which improved rapidly. The safety of esaprazole was good, no modifications of laboratory parameters being observed. Although the study involved only a small number of patients, the findings obtained indicate the potential usefulness of esaprazole in the treatment of gastric ulcer.     

奥美拉唑和西咪替丁治疗危重病儿应激性溃疡出血的随机对照试验

目的 :探讨奥美拉唑治疗危重病儿应激性溃疡出血的临床疗效。方法 :将 82例应激性溃疡出血的危重病儿随机分为奥美拉唑治疗组 4 7例 [男性2 5例 ,女性 2 2例 ,年龄 (6±s 3)a]和对照组 35例[男性 19例 ,女性 16例 ,年龄 (5 .9± 2 .8)a]。 2组均给予病因、对症及支持治疗 ,同时治疗组给予奥美拉唑 0 .6～ 0 .8mg·kg- 1,每日 1次口服或经胃管注入 ,连用 3～ 5d。对照组给予西咪替丁每日 10～ 2 0mg·kg- 1,静脉输注 ,连用 3～ 5d。观察应激性溃疡出血临床好转情况 ,同时观察不良反应的发生情况。结果 :奥美拉唑治疗组 ,显效 4 2 % ,有效 4 7% ,无效11% ,总有效 89% ;对照组 ,显效 14% ,有效4 6% ,无效 4 0 % ,总有效 60 % ,2组相比差异有非常显著的意义 (P <0 .0 1)。结论 :奥美拉唑治疗危重病儿应激性溃疡出血疗效显著 ,且不良反应少     

健脾益胃汤治疗胃溃疡的临床价值分析

目的研究健脾益胃汤治疗胃溃疡的临床价值。方法选取我院2014年3月~2015年6月就诊的83例胃溃疡患者。根据随机分组方法将患者分为西医组和中西医组。西医组以西医常规药物进行干预;中西医组在西医组基础上增加健脾益胃汤治疗。比较(1)胃溃疡愈合率、治疗总有效率;(2)不良反应发生率、1年复发率;(3)干预前和干预后患者腹部疼痛、反胃、嗳气、灼热症状评分的差异。结果 (1)中西医组对比西医组胃溃疡愈合率、治疗总有效率更高,差异有统计学意义(P0.05);(2)中西医组、西医组不良反应发生率相似,差异无统计学意义(P0.05);中西医组1年复发率明显低于西医组,差异有统计学意义(P0.05);(3)干预前两组腹部疼痛、反胃、嗳气、灼热症状评分相似,差异无统计学意义(P0.05);干预后中西医组对比西医组腹部疼痛、反胃、嗳气、灼热症状评分改善更显著,差异有统计学意义(P0.05)。结论健脾益胃汤治疗胃溃疡的临床价值高,可有效改善患者临床症状,对预防胃溃疡复发效果确切,可减轻患者反复患病痛苦和医疗负担,且治疗的安全性高,值得推广。     

Lafutidine can improve the quality of gastric ulcer healing in humans: a randomized, controlled, multicenter trial

Improving the quality of ulcer healing (QOUH) is one of the valid methods of prevention of relapse of gastric ulcers. We investigated the effect of lafutidine on the QOUH of gastric ulcer compared with famotidine in a randomized, multi-centre controlled trial. Consecutive 80 patients with a gastric ulcer were randomly assigned to receive twice daily either lafutidine (10 mg) or famotidine (20 mg) for 12 weeks. Esophagogastroduodenoscopy was performed to examine the ulcer healing rate and rate of fl at type ulcer scars using dye-contrast. The gastric ulcer healing rate was 92.1% in the lafutidine group (35/38) and 94.7% in the famotidine group (36/38). The rate of flat-type ulcer scars was significantly higher in the lafutidine group (68.4%, 26/38) than in the famotidine group (42.1%, 16/38) (P = 0.021). In conclusion, the present study demonstrated that lafutidine, as compared to famotidine, yields a signifi cantly superior QOUH in patients with gastric ulcers in the clinical setting. Received and accepted 3 August 2006     

Rioprostil: a clinical experience in gastric ulcer treatment

The efficacy and tolerability of the prostaglandin E1 derivative rioprostil (Bay o 6893) was studied in a randomized, double-blind, placebo-controlled trial in 40 patients affected by acute gastric ulcer. At the end of the eight weeks period ulcer healing was achieved in 85% of the rioprostil-treated patients and in 60% of the placebo-treated ones (p less than 0.05). Rioprostil produced a significant reduction of pain and also improved the clinical status. This positive outcome was noted both in smokers and in non-smoking patients, while only this last group improved during the placebo treatment.     

Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial

We studied the effectiveness of lansoprazole and ranitidine in promoting gastric ulcer healing in a multicentre double-blind trial, by comparing the proportion of healed ulcers after 4 and 8 weeks of treatment. One hundred and fifty-eight patients were randomly given either ranitidine (150 mg each morning and at bedtime) or lansoprazole (30 mg each morning and placebo at bedtime). One hundred and twenty-eight patients completed the trial (62 taking lansoprazole, 66 taking ranitidine). Fifty-one (80%) of those treated with lansoprazole and forty-two (62%) of those treated with ranitidine had healed ulcers at 4 weeks (P < 0.05). Sixty-one (98%) patients who received lansoprazole and 57 (86%) who received ranitidine had healed ulcers at 8 weeks (P < 0.05). The observed differences were not significant in the intention-to-treat analysis. No serious adverse event was reported with lansoprazole.     

A trial of lansoprazole in refractory gastric ulcer.

BACKGROUND: The proton-pump inhibitor, lansoprazole, a more potent gastric acid inhibitor with a longer action than H2-receptor antagonists, should heal refractory gastric ulcers more effectively. METHODS: Lansoprazole's efficacy in healing refractory gastric ulcer(s) (i.e. after 6 weeks of treatment with H2-receptor antagonists, antacids or sucralfate at recommended dosages, and/or a relapse within 1 year of documented gastric ulcer), was compared by a two-dose regimen in a four- centre, randomized, parallel group study. One hundred and eighteen patients (59 per group) with an endoscopically confirmed gastric ulcer > or = 3 mm, received lansoprazole 30 or 60 mg daily. We assessed efficacy endoscopically at 4 and 8 weeks, and again after documented healing during a maintenance phase of lansoprazole 30 mg/day at 2 and 4 months. RESULTS: Demographic and anthropometric data were comparable. Healing rates at 4 weeks were 63% (30 mg) vs. 66% (60 mg) (95% CI, -14 to 21%) and cumulatively at 8 weeks, 83% (30 mg) vs. 81% (60 mg) (95% CI, -12 to 16%). Two and 4 months after documented healing, 86% and 78% of intention-to-treat patients remained in remission. CONCLUSION: Lansoprazole 30 or 60 mg/day appear equally effective in healing refractory gastric ulcers, while maintenance therapy of 30 mg/day effectively prevented an ulcer relapse.     

Effects of ranitidine on quality of gastric ulcer healing compared with famotidine: a randomized, controlled, multicenter trial

Ranitidine has been found to have anti-inflammatory action as well as antisecretory action in experimental models. However, there are no reports in human gastric ulcer. The aim of this study was to investigate the effects of ranitidine compared with those of famotidine on the quality of gastric ulcer healing. We randomly assigned 69 consecutive patients with gastric ulcers to ranitidine (n = 34) or famotidine (n = 35) for 12 weeks, with endoscopic assessment of the quality of gastric ulcer healing and histological assessment of gastric mucosa 12 weeks after treatment started. Ulcer healing rates of over 95% were very similar in the two groups. The rates of ulcer scars with a flat pattern (good-quality healing) were significantly higher in the ranitidine group than in the famotidine group (per protocol, 63.0% and 34.5%, p = 0.033). The neutrophil infiltration score in the body mucosa treated with famotidine, but not ranitidine, significantly increased after treatment. In contrast, the mononuclear cell infiltration score in the antral mucosa treated with ranitidine, but not in that treated with famotidine, had significantly decreased. In conclusion, initial therapy with ranitidine significantly improved the quality of gastric ulcer healing and the histological scores of gastric mucosa compared with famotidine.     

Cimetidine in patients with gastric ulcer: a multicentre controlled trial.

Forty-five adult outpatients with endoscopically confirmed gastric ulceration completed a double-blind trial of either cimetidine (1 g/day) or placebo. After six weeks 18 of the 23 patients receiving cimetidine showed complete ulcer healing compared with only six of the 22 patients receiving placebo. The cimetidine group also had fewer days with pain than the placebo group but the difference was not statistically significant. Cimetidine therefore seems to promote healing of gastric ulcers without severe side effects, although its effect on pain is less pronounced than in patients with duodenal ulcers.     

坤泰胶囊治疗围绝经期妇女症状的随机双盲双模拟平行临床试验

目的 研究坤泰胶囊与雌激素对围绝经期妇女症状的疗效及安全性。方法 用随机双盲双模拟平行临床研究,80例围绝经期患者分为实验组(坤泰胶囊)和对照组(戊酸雌二醇),治疗时间3个月。用药前后分别用Kuppermen评分评价药物疗效。结果 用药3个月后,围绝经期症状得到明显改善,坤泰组和戊酸雌二醇组各有51.5%和66.7%的患者潮热症状完全缓解。药物不良反应主要为胃不适。结论 坤泰胶囊与小剂量雌激素对围绝经期妇女疗效相似。     

Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease -- results from a randomized trial programme

BACKGROUND: Helicobacter pylori infection has been proposed as a protective factor against the development of gastro-oesophageal reflux disease. AIM: To study heartburn and endoscopic findings before and after H. pylori eradication therapy in patients with peptic ulcer disease. METHODS: In a multicentre trial programme, patients (n = 1497) were randomized to the omeprazole triple therapy group or to the control group, and were followed for 1-6 months after treatment. Patients in whom the infection was eradicated were compared with those in whom infection persisted. The severity of heartburn was measured at baseline and at each return visit. Endoscopy was performed 6 months after therapy in two of the five studies. RESULTS: In patients with duodenal ulcer, there was a significantly lower prevalence of heartburn after successful eradication of H. pylori relative to that after failed eradication (estimated odds ratio, 0.48). The reduction in the prevalence of heartburn in patients with gastric ulcer was independent of the post-treatment H. pylori status. In studies in which ulcer relapse was included in the model, this factor emerged as a significant factor for heartburn. The observed incidence of oesophagitis at the last visit was not influenced by H. pylori status. CONCLUSIONS: Eradication of H. pylori in patients with peptic ulcer disease was associated with a reduced prevalence of heartburn. Prevention of ulcer relapse could be the true cause of this reduction.     

利培酮和氟哌啶醇随机双盲治疗痴呆的行为和精神症状

目的 :评价利培酮和氟哌啶醇治疗痴呆的行为和精神症状的疗效和安全性。方法 :采用随机双盲对照研究 ,利培酮组 2 8例 ,剂量 (1.3±s 0 .5 )mg·d- 1,0 .5～ 2mg·d- 1。氟哌啶醇组 2 5例 ,剂量(2 .8± 0 .9)mg·d- 1,1～ 4mg·d- 1,疗程均 8wk。治疗前后进行阿尔采末病病理行为评分表 (BE HAVE AD)、Cohen Mansfield激越问卷 (CMAI)等量表评定及实验室检查。结果 :2组病人治疗后BEHAVE AD和CMAI评分显著下降 (P <0 .0 1) ,2组病人之间治疗后的BEHAVE AD和CMAI减分值无显著差异 (P >0 .0 5 )。 2组病人的不良反应均以锥体外系反应为主 ,利培酮组 2 3% ,氟哌啶醇组4 0 %。结论 :低剂量的利培酮和氟哌啶醇治疗BPSD疗效确切 ,病人耐受性好。     

Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial

Rational

It has been suggested that phosphodiesterase 5 inhibitors such as sildenafil may be effective in the treatment of negative symptoms of schizophrenia.

Objective

This study was designed to investigate the effect of sildenafil added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind and randomized clinical trial.

Methods

Eligible participants in the study were 40 patients with chronic schizophrenia with ages ranging from 18 to 45?years. All patients were inpatients and were in the active phase of the illness and met DSM-IV-TR criteria for schizophrenia. Patients were allocated in a random fashion: 20 to risperidone (6?mg/day) plus sildenafil (75?mg/day) and 20 to risperidone (6?mg/day) plus placebo. The principal measure of outcome was Positive and Negative Syndrome Scale (PANSS).

Results

Although both protocols significantly decreased the score of the positive, negative, and general psychopathological symptoms over the trial period, the combination of risperidone and sildenafil showed a significant superiority over risperidone alone in decreasing negative symptoms and PANSS total scores over the 8-week trial (between-subjects factor; F?=?4.77, df?=?1; P?=?0.03; F?=?5.91, df?=?1, P?=?0.02 respectively).

Conclusion

Therapy with 75?mg/day of sildenafil was well tolerated, and no clinically important side effects were observed. The present study indicates sildenafil as a potential adjunctive treatment strategy for treatment of negative symptoms of schizophrenia. This trial is registered with the Iranian Clinical Trials Registry (IRCT1138901151556N11).     

Proximal gastric vagotomy: interim results of a randomized controlled trial.

In a randomized controlled trial 50 patients with duodenal ulcer treated by proximal gastric vagotomy (P.G.V.) without drainage were compared with 50 who underwent selective vagotomy and gastrojejunostomy. The clinical results were assessed in 99 patients one to four years after operation. Patients who had undergone P.G.V. had significantly less dumping, nausea, and bile vomiting and fared better in their overall clinical grading. The postoperative Visick grading of the 50 patients with P.G.V. was similar to that of 56 controls with no known gastrointestinal disease who had not undergone operation. The results obtained in the patients who had had P.G.V. without drainage were compared with those of a further group of 24 patients subjected of P.G.V. with gastrojejunostomy, and the better results obtained in the former group were thought to be due to elimination of the drainage procedure. The average follow-up period of the trial was just over two years, but there were no indications that the recurrent ulceration rate after P.G.V. would be any higher than after other types of vagotomy and drainage.